Hepatitis C virus inhibitors

US8362020B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Omar D. Lopez · Wallingford, US
• Denis R. St. Laurent · Newington, US
• Jason Goodrich · Meriden, US
• Jeffrey Lee Romine · Meriden, US
• Michael H. Serrano-Wu · Cambridge, US
• Fukang Yang · Madison, US
• Ramesh Kakarla · Doylestown, US
• Xuejie Yang · Longbeilingcun, CN
• Yuping Qiu · Princeton Junction, US
• Lawrence B. Snyder · Killingworth, US

Key dates

• Filing date: Dec 21, 2010
• Grant date: Jan 29, 2013
• Expiry date: Dec 21, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein.